BioNTech and Ryvu Therapeutics have collaborated on several research programs

BioNTech and Ryvu Therapeutics have established cooperation in the development of several research programs, the aim of which is to develop small-molecule compounds with therapeutic potential using the mechanism of immunotherapy, the companies announced in a joint statement. In addition, the companies entered into an exclusive licensing agreement to develop a portfolio of standalone small molecule STING agonists discovered and developed by Ryvu. Ryvu will receive over PLN 186 million (EUR 40 million) from BioNTech, which consists of an upfront payment of PLN 93 million (EUR 20 million) and PLN 93 million (EUR 20 million) as an equity investment.

BioNTech will also fund Ryvu's collaborative research. In addition, Ryvu is eligible to receive payments for reaching R&D and commercialization milestones, as well as single-figure royalties on drug sales resulting from the collaboration.

“Ryvu is excited to bring its knowledge and experience in the field of immuno-oncology to the collaboration with a world leader in the development of immunomodulatory targeted therapies. BioNTech's experience in the field of mechanisms that modulate the activity of the immune system perfectly fits into the Ryvu research platform. We are sure that thanks to our combined knowledge, we will be able to develop diverse, therapeutically effective and safe molecules,” said Paweł Przewięźlikowski, CEO and co-founder of Ryvu Therapeutics.

BioNTech (Biopharmaceutical New Technologies) is a new generation immunotherapy company, a pioneer in the field of innovative cancer therapies and treatment of other serious diseases.

Ryvu Therapeutics was founded in 2007 (as Selvita). It is a Polish biotechnology company developing innovative small molecule compounds with therapeutic potential in oncology. Ryvu Therapeutics is listed on the main market of the Warsaw Stock Exchange.

Our privacy policy